Rebecca Luse

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Deep Track Capital LP provides investment advice. The private company is based in Greenwich, CT and has subsidiaries in Cayman Islands. The company was founded in 2020 by David Eric Kroin. David Eric Kroin has been the CEO since 2020.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.